Teladoc (TDOC): Phone a Doctor Anytime For $40

With increasing health care costs, innovative ways to save money through the use of technology are transforming the health care industry. The remote treatment of patients and centralized patient data are examples of applying technology to decrease costs and improve patient care. Companies like Propeller Health and Adherium have built “smart inhalers” that can remotely monitor a patient’s adherence to a prescribed medication. Artificial hearts from SynCardia allow patients waiting for transplants full mobility so they can wait for their heart transplant at home or anywhere else. One company which has emerged as a leader in “telehealth“, or the ability to speak with a doctor 24/7, is Teladoc.

About Teladoc

Click for company website

Founded in 2002, Teladoc (NYSE:TDOC) is the nation’s first and largest provider of telehealth services having taken in $74 million in venture funding. In the past several years, Teladoc has acquired four of their competitors;  Consult A Doctor, AmericDoc, StatDoc and BetterHelp. Just last month, Teladoc raised $163.5 million with a very successful IPO which gives them a market cap today of $1 billion. If you had invested in Teladoc on the day their IPO debuted, your investment would be up +7% today provided that you were lucky enough to buy at the lowest price of the day which was $25.91. So what potential does the TDOC solution have going forward?

The TDOC solution connects their 11 million unique members to over 1,100 board-certified physicians and behavioral health professionals. These “Teladocs” can be accessed any time of day or night at a cost of $40 per visit payable by credit card. The solution is delivered with a median response time of less than ten minutes from the time a member requests a telehealth visit to the time they speak with a TDOC physician. TDOC provided 274,000 telehealth visits in the first six months of 2015 compared to approximately 300,000 telehealth visits for all of 2014. Below are some of the key metrics provided by TDOC:


What’s interesting about the TDOC business model is that they generate in excess of 80% of their revenue from clients who purchase access to their “dial-a-doc” network for their employees, dependents and other beneficiaries. These subscription access fees are on a per-member-per-month basis along with a visit fee for each completed visit. With names such as PepsiCo and Bank of America on board, TDOC has built up a diversified U.S. only client base with no one client accounting for more than 10% of their revenues. In Q2 2015, TDOC realized $18 million in revenues up +78% from the $10 million they received in Q2 2014. However, Marketing and General Admin expenses increased +220% and +300% respectively compared to the previous year leading to a Q2 2015 loss of around $16 million. With such a sharp increase in expenses, TDOC  anticipates negative EBITDA results through the end of 2017.


Teladoc seems to dominate the “telehealth” space as they continue to acquire their competitors. With the $163.5 million cash raised through their IPO, TDOC is in a position to continue acquiring any competitive threats going forward and this remains an interesting space to watch.

Want to know what 30 tech stocks we own right now? Want to know which ones we think are too risky to hold? Become a Nanalyze Premium member and find out today!  

4 thoughts on “Teladoc (TDOC): Phone a Doctor Anytime For $40
  1. Recently I found another similar interesting stock:
    Doctor Care Anywhere (DOC.AX)
    I think it is a good buy right now.
    Maybe you want to cover it in your article ?

    1. We’re holding the leader in telemedicine at the moment – Teladoc – and consequently we have little interest in the many small competitors running around, especially when they fall below our market cap cutoff of $1 billion. We’re not hurting for companies to write about at the moment.

  2. Argus Research Corporation upgraded Teladoc from hold to buy and placed a $95 price target on the stock, citing an improved financial outlook as its reason.
    According to Argus’ Report: “After years of operating losses despite robust revenue growth, Teladoc is now on a clear path to profitability,” adding that the company’s Q4 2021 results indicated “a rise in membership, utilization and per member revenue.”
    Current share price: $63.94.

    1. Analyst price targets are largely useless, especially when they don’t represent anything but a point in time. So when it hits that price target, do we sell? Hold? Buy more? Price targets are useless and so is advice from any analyst who thinks they can time the market. We’re holding the company long and may revisit the thesis soon since their 2021 results are out.

Leave a Reply

Your email address will not be published.